Siska Van Bruwaene

@SiskaVB @EveraertsW @piet_ost @shanekronos It’s quite amazing!! PLND appears to have disappeared from the updated Prostate Cancer #EAUGuidelines! Now aligns with practice in Australia 10 years into the PSMA era #EAU24

@declangmurphy @EveraertsW @piet_ost @shanekronos So … I indeed cannot seem to find a recommendation anymore in favor of PLND in the new guidelines 😮 I must admit I am a bit confused, what should we fight against now 🤷‍♀️😁

@EveraertsW @piet_ost @shanekronos @SiskaVB I think 2024 may see the end of widespread overuse of ePLND. So many useless PLNDs, driven by guidelines over-promoting nomograms and presuming benefit. “Do ePLND if nomogram says >7% LNI”?? I think not. Especially with high NPV of PSMA in intermediate risk #eau24 #eauguidelines

Do extended lymph node templates provide any benefit in radical prostatectomies? ✅ ePLND templates may provide therapeutic BCR benefits and higher rates of detecting positive lymph nodes in patients undergoing radical prostatectomy. ePLND has different definitions depending depending on the source - ✅ Obturator fossa + internal iliac + external iliac + common iliac ± presacral nodes have the highest node yield, positive rates, and superior reduction in BCR.   ✅ There is a potential benefit in removing more lymph nodes during radical prostatectomy. However, more research is needed to determine whether this strategy benefits certain patient groups. Recent RCT data is inconclusive. eu-focus.europeanurology.com/article/S2405-… @bcm_urology @UroOnc @EurUrolFocus @UroDhino @GalSaffatiMD @JustinBadal @JeremySlawin #BCMUrology #Urology #UroSoMe #oncology #cancer #urologist

🔬💊 #TherapeuticNodeYield ➡️ #WillRogers 🤠 + #BiasMirage 🔮 as long anticipated pubmed.ncbi.nlm.nih.gov/36573245/ @KBGinsburg #ASCO23

🔬ePLND in #BladderCancer 🏥 😞 More harm. ❌Zero benefit 📚Level I evidence from @SWOG👩‍⚕️👨‍⚕️ meetings.asco.org/abstracts-pres… (tnx @KBGinsburg for alway being the first to find the good stuff!) #ASCO23 @ASCO

@DrDeanElterman @MaartenAlbersen @MikkelFode @faysal_a_yafi @cgratzke Damn, missed you at EAU!!

Plenary: Debunking the data on #PRP for #ED by @MikkelFode Promising area for sure but data is lacking. “Regenerative Injectables” remain investigational. Beware “snake oil” on the internet #EAU23 @faysal_a_yafi @MaartenAlbersen @cgratzke

ProtecT 15 yr: ⁦@Freddie_Hamdy⁩ taking on misconceptions, and conclusions. #eau23 Thoughts #pcsm??

Check out our latest paper on "Quality Control Indicators for TURBT" #bladdercancer @EurUrolOncol authors.elsevier.com/c/1gHHb9Cfv-t-… @CaBLe_UZL @TimMuilwijk @FrankVanderAa6 @joniau @yraskin @SiskaVB @KathyVanderEeckt @BenVanCleynenbreugel @CedricJorissen @UZLeuven @VznkuL

15yr f/u for #ProtecT_Trial just out! •n=1610 •1/3 IR or HR by NCCN criteria •n=45 DS deaths (AM17:RP12:RT16) •n=104 mets (AM51:RP26:RT27) •n=151 started ADT (AM69:RP40:RT42) •62% of AS cross over to radical Surprised? Or no surprises?? #EAU23 #Oxford_Urology @BAUSurology

@LambAlastair @BAUSurology @Freddie_Hamdy @NEJM @NDSurgicalSci @OxfordMedSci @dr_coops @SigridCarlsson @BJUIjournal @OxfordCancer @JimCatto @LabBryant So 62% of active treatment in AS group and still double risk of mets. That’s not reassuring (if avoiding mets would be the goal of course).

Guess this is key slide from Freddie's talk. It's given me a bit of an existential crisis over past 36hrs Should we approach all localised #ProstateCancer like we now do salvageRT? i.e. put EVERYONE on surveillance, then only treat those who 'progress'?? (1/3 were T3!) #EAU23

Lymphedema after prostate cancer treatment? For many, it remains the forgotten vascular disease. 👉 Find out in our systematic review mdpi.com/1953218 #mdpicancers via @Cancers_MDPI @joniau @EveraertsW @LisaMoris2

When low-volume on conventional imaging goes into high-volume on next-generation imaging in #mHSPC - treat like low-volume. #APCCC22 presentation by @fizazi_karim @GustaveRoussy. #ReadNow on UroToday > bit.ly/3RgVCLs @APCCC_Lugano @Silke_Gillessen @AOmlin

Late breaking abstracts #ASTRO22 - @ChadTangMD EXTEND trial; oligometastatic #prostatecancer. Intermittent ADT + SABR versus ADR alone extends PFS, but importantly time men enjoy off ADT in the long term (eugonadal PFS). Important patient centric endpoint! 👏🏽⭐️ @OncoAlert #pcsm

@Prof_Nick_James on the association between volume & radiotherapy in #metastaticprostatecancer Is 4 the magic no for mets? How important is LN burden? Can men with mets be cured? 🤔 #PROSCA22 @mirrorsmed

Just when you thought to grasp oligo-metastatic disease …@juliarmurray helping to see the light #PROSCA22

D2 #PROSCA22 in beautiful Athens @Silke_Gillessen outlines the evidence for #docetaxel in #mHSPC Is volume of disease important? Does it matter if synchronous v metachronous disease? Triple v doublet therapy? @mirrorsmed @Prof_Nick_James

Amit Bahl warning to perform imaging in mCRPC even when PSA is stable. #PROSCA22

@AlbertoBossial gives us surgeons an important task : organize some phase III trials like we do 😁 #PROSCA22

Some Stampede high risk patients might be cured with surgery alone instead of ‘suffering’ 2 years of intensified hormonal treatment. #PROSCA22 @joniau excellent talk

@Achard_Verane Very clear talk at #PROSCA22 PSMA in BCR setting is interesting but creates a lot of new questions!